PubMed · 1997 · 16 citations · 12 references
Life SciencesInfectious DiseasesEpidemiologyMolecular VirologyVirologyViral EpidemiologyViral InfectionsCommunity Prevalence
Infection with HTLV-II is endemic in Amerindians, with prevalence ranging from 0.89% - 33%. To determine the prevalence of HTLV-II among indigenous Mayans in the Yucatan Peninsula of Mexico, 440 indigenous Mayans were recruited, all native to and residents of one of six Mayan communities in the Yucatan Peninsula, (Xohuayan n=144, Yaxachen n=101, Kanxoc n=84, Xocen n=40, Nabalan n=46 and X'calot n=25) between May, 1992 and June, 1993. All of the above are pre-Hispanic settlements located in tropical forest with no immigrations for over 50 years. Of the 440 indigenous Mayans, only one woman from the X'calot tribe (0.23%) was shown to be infected with HTLV-II. A high percentage of indeterminate results was found (22/439, 5%), three of which were accounted for by the husband and two children of the positive female case. PCR analysis followed by specific restriction digestion demonstrated the virus to be of the HTLV-IIb subtype, similar to that described in the Guaymi Indians from Panama. The presence of HTLV-II in the Mayan ethnos, and in other Amerindian populations supports the idea that HTLV-II is an ancestral virus in America and that it has been sustained in "closed" communities.
12
Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao et al. · Cancer Discovery · 2015 · 916 citations · Full text
Medicine, Immunology, Oncology +17
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text
Medicine, Oncology, Pharmacology +15
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon, Jeffrey W. Clark, Jared Weiss et al. · Nature Medicine · 2020 · 393 citations · Full text
Medicine, Oncology, Pharmacology +12